GSK Scores Proteomics In Cellzome Acquisition | Chemical & Engineering News
Volume 90 Issue 21 | p. 19 | Concentrates
Issue Date: May 21, 2012

GSK Scores Proteomics In Cellzome Acquisition

Department: Business
Keywords: proteomics, acquisition, drug development

GlaxoSmithKline has agreed to acquire the shares it does not currently own in Cell­zome to access the latter’s proteomics platform for drug development. GSK currently owns just less than 20% of Cellzome through previous drug development collaborations. It will pay about $99 million for the rest of the company. Cellzome’s proteomic mass spectrometry and screening technology has been deployed in early-stage research on immune-inflammation therapies at GSK. The deal marks GSK’s third acquisition of a platform technology in the past five years. In 2007, the drug firm acquired Domantis, a developer of next-generation antibody therapies, and Praecis, a specialist in chemical synthesis and screening technologies. GSK and Cellzome shareholders plan to create a spin-off company retaining the rights to Cellzome assets that GSK does not plan to pursue.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment